NCT04230148 - Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older). | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

February 11, 2022

Primary Completion Date

December 10, 2026

Study Completion Date

December 10, 2026

Conditions

Fascioliasis

Interventions

DRUG

Egaten (Triclabendazole) 250 mg tablets

Egaten 250 mg scored tablets for oral use.

Trial Locations (10)

COMPLETED

Novartis Investigative Site, San Martín de Porres

RECRUITING

Novartis Investigative Site, Cusco

COMPLETED

Novartis Investigative Site, Cairo

RECRUITING

Novartis Investigative Site, Alexandria

RECRUITING

Novartis Investigative Site, Diyarbakır

RECRUITING

Novartis Investigative Site, Gaziantep

RECRUITING

Novartis Investigative Site, Istanbul

RECRUITING

Novartis Investigative Site, Van

RECRUITING

Novartis Investigative Site, Qui Nhon

RECRUITING

Novartis Investigative Site, Medellín